OBJECTIVE: To investigate the effects of growth hormone (GH) de®ciency on serum lipid and leptin concentrations in hypopituitary patients taking conventional replacement therapy and to determine the relations between leptin and gender and anthropometric and metabolic variables. SUBJECTS: Twenty-one GH de®cient adult hypopituitary patients (15 women, six men) and 21 (14 women, seven men) age, sex and body mass index (BMI) matched healthy controls. MEASUREMENTS: After an overnight fast, anthropometric parameters were measured and body composition was determined by a bioelectrical impedance analyser. Venous blood samples were obtained for the measurements of glucose, total cholesterol, high density lipoprotein (HDL) cholesterol, triglyceride, intact insulin, insulin-like growth factor 1 (IGF-1) and leptin concentrations. Serum leptin and hormones were analysed by radioimmunoassay. RESULTS: Hypopituitary patients with GH de®ciency showed signi®cantly higher triglyceride, total and low density lipoprotein (LDL) cholesterol and lower HDL cholesterol concentrations on conventional replacement therapy. The unfavourable lipid pro®le was particularly evident in women. Signi®cantly higher leptin concentrations were found in patients compared with healthy controls with similar body fat content (23.5 AE 11.8 ngaml vs 11.7 AE 6.9 ngaml, P 0.01). This difference remained signi®cant even when leptin values were expressed in relation to fat mass percentage (0.79 AE 0.40 vs 0.42 AE 0.17 ngaml%, P`0.05) and fat mass kg (1.32 AE 0.81 vs 0.66 AE 0.30 ngaml kg, P`0.05). Signi®cant positive correlations were observed between leptin concentrations and body fat percentage and age in the control group. In patients the sole signi®cant relation between leptin and study parameters was the positive correlation observed between leptin and total cholesterol concentrations. Serum leptin concentrations were signi®cantly higher in women than men in the control group, but not in the patients. No signi®cant gender difference was observed when leptin concentrations were expressed in relation to fat mass (percentage and kg). CONCLUSION: Growth hormone de®cient hypopituitary patients (particularly women) on conventional replacement therapy have a more atherogenic lipid pro®le. Leptin concentrations are increased in GH de®cient adults even after adjustment for percentage body fat and body fat mass (kg). Although the nature of our data does not allow us to draw any conclusions on the mechanism(s) of increased leptin concentrations in GH de®ciency, decreased central sensitivity to leptin and increased leptin production from per unit fat mass, or alterations in leptin clearance, might be operative.
Introduction
Leptin, the product of the ob gene, is produced by adipocytes and plays a critical role in the regulation of body fat. 1 Leptin is thought to act in an endocrine manner by the means of reporting the size of adipose tissue mass to the hypothalamus. It serves both as an index of fat mass and a sensor of energy balance. 1 ± 4 Serum leptin concentrations in obese humans have been found to be higher than in normal-weight subjects and correlated with percentage body fat, suggesting that obese humans are insensitive to the central action of endogenous leptin. 5 Regulation of leptin production in humans is poorly understood, but appears to depend on total body fat, changes in energy intake and plasma insulin concentrations. 6 Recent reports also indicate an interaction between the growth hormone (GH) and leptin systems. 2,6 ± 14 The interaction between leptin and GH is thought to be complex. Growth hormone status might directly or indirectly in¯uence leptin secretion. Growth hormone is an important regulator of insulin secretion and increases energy expenditure. 2, 6, 8, 12 Abnormal body composition with increased fat mass and decreased lean mass is a well-documented feature in adults with hypopituitarism despite conventional replacement therapy. 10,15 ± 17 Increased fat mass and decreased lean body mass are reversed by GH treatment in GH-de®cient humans. 16 ± 17 The results of the studies on the effect of GH on serum leptin concentrations are con¯icting. Acute GH exposure in GH de®cient patients 6 or healthy subjects 8 may cause a modest increase in leptin concentrations under certain conditions. Serum leptin concentrations were not in¯uenced by more prolonged GH administration in one of these studies. 6 In other studies, GH treatment lowered serum leptin concentrations both in GH de®cient patients 7, 11 and abdominally obese men. 2 In acromegalics lower leptin concentrations were found, suggesting that chronic exposure to high GH secretion may decrease plasma leptin. 13, 14 Patients with hypopituitarism (particularly women) receiving conventional replacement therapy have higher cardiovascular mortality and morbidity than the general population. 18, 19 Premature atherosclerosis of the peripheral arteries and the aorta, 20 myocardial dysfunction and abnormal exercise tolerance 21, 22 have been described in symptom-free hypopituitary patients. The mechanisms of increased vascular disease in hypopituitarism and the causal relationship to GH de®ciency are unclear. However changes in carbohydrate and lipid metabolism and body composition are likely to play a major role. 23 Several studies have demonstrated an increased prevalence of cardiovascular disease risk factors in hypopituitary adults. 23 ± 26 The aim of this study is to determine the effects of GH de®ciency on serum lipid and leptin concentrations in hypopituitary patients taking conventional replacement therapy and to compare patients' ®ndings with healthy age, sex and weight matched controls.
Materials and methods

Study population
Twenty-one hypopituitary adults and 21 normal subjects participated in the study. The patients and controls were matched for age, sex and body mass index (BMI, Table 1 ). Patients were recruited from the Endocrine Clinic of Internal Medicine at Istanbul Faculty of Medicine. Controls were recruited from hospital staff and friends. The study was performed according to the Declaration of Helsinki.
Hypopituitarism resulted in most patients from pituitary or peripituitary disease treated medically (n 11), surgically (n 1) or surgery with radiotherapy (n 9). The causes of pituitary de®ciencies are listed in Table 2 .
All patients were stable on conventional replacement treatment for at least 6 months before the study. The patient with previous Cushing's disease had not had active Cushing's disease for at least a year.
All patients were taking conventional replacement therapy consisting of L-thyroxine, glucocorticoids, sex hormones except for postmenopausal women and desmopressin where necessary. Five patients were postmenopausal. In the control group three women were postmenopausal (P NS). Other women of the control group had regular menstrual cycles. Growth hormone treatment had not been given to any of the patients previously.
Growth hormone de®ciency was determined according to the following criteria: 1) IGF-1 levels lower than mean 7 2 s.d. of control group (`42.5 ngaml) andaor 2) maximum stimulated serum GH concentrations lower than 5 ngaml in response to previously administered oral L-dopa. All patients were GH de®cient according to these criteria.
Replacement doses had been optimized previously for the individual patients on the basis of clinical and biochemical evaluation and serum hormone concentrations. This regimen was continued in the present study. Glucocorticoid replacement was taken as prednisolone tablets twice daily with a dose range of 5 ± 7.5 mga24 h. L-Thyroxine was given with a dose range of 100 ± 150 mga24 h. The ef®ciency of the given L-thyroxine doses was determined by the measurement of serum free thyroxine concentrations. Male sex hormone was taken as i.m. depot testosterone (250 mg) at 3 ± 4 week intervals. Of the female patients, 10 were receiving sex hormone replacement. Five postmenopausal women did not receive sex hormone treatment. None of the control women (including postmenopausals) was receiving sex hormone preparations. Sex hormone replacement was either a combined oral contraceptive preparation or conventional combined replacement therapy. No patient or control had any other known illness and no medication other than conventional replacement therapy was given to patients or controls.
Protocol
Patients and controls attended the Endocrinology Clinic of Internal Medicine Department at 08:30 
Body composition
Body weight was measured with the patients and subjects dressed in light clothes without shoes and was determined to the nearest 0.1 kg on a calibrated beam scale. Body height was measured to the nearest 0.01 m in the standing position. BMI was calculated as body weightaheight. 2 Waist circumference was measured at the midpoint between the lower costal margin and the iliac crest, and hip circumference as the greatest circumference around the buttocks using a non-elastic tape with the subjects standing. Measurements were recorded to the nearest centimetre. Waistto-hip ratio (WHR) was calculated as waist circumference divided by hip circumference.
Body composition was measured by a bioelectrical impedance analyser (Bodystat 1500, Bodystat Ltd, Douglas, Isle of Man) after an overnight fast with an empty bladder and in the morning when the anthropometric measurements and blood samples were taken. This measurement was based on the reactance and resistance of the body to the passage of the direct current of 50 Hz frequency and 500 mA amplitude.
Patients stayed in the recumbent position with the usual clothes. Arms and legs were abducted and electrodes placed on standardized locations of the right hand and foot. According to the attenuation of the direct current when passing through the body, fat mass, lean mass and water mass of the body were calculated and the results appeared on the device's screen. This method has been validated previously and within-day and between-day measurements have been reported to have high reproducibility. 27, 28 Biochemical and hormonal analyses Venous blood samples were taken after an overnight fast between 8 and 9 a.m. All biochemical analyses including glucose, total cholesterol, and triglyceride concentrations were performed with a technicon DAX-72 autoanalyser (Technicon, Bayer Corporation, Tarrytown, New York) in the Central Biochemistry Laboratory, Istanbul Faculty of Medicine. HDL cholesterol concentrations were also measured at the RA-XT autoanalyser after phosphotungstic acid and magnesium chloride precipitation. LDL cholesterol was calculated by Friedewald formula.
Insulin analyses were performed by radioimmunoassay (RIA) using a commercially available kit (Diagnostic Systems Laboratories, Webster, Texas, USA). Serum free thyroxine concentrations were analysed using ligand analogue RIA (Amerlex-M, Amersham International). Growth hormone was measured with a conventional RIA kit (Euro-Diagnostica, Arnhem, The Nerherlands).
Serum IGF-1 concentrations were determined by a hydrochloric acid ± ethanol extraction RIA (Diagnostic Systems Laboratories, Webster, Texas, USA). The intra-assay coef®cients of variation were 3.4% and 1.5% at serum concentrations of 9.4 and 263 ngaml, respectively. The inter-assay coef®cients of variation were 8.2% and 3.7% for IGF-1 concentrations of 10.4 and 256 ngaml, respectively.
Serum leptin concentrations were determined by a human leptin RIA (Linco Research Inc., St Charles, MO, USA). The limit of sensitivity for the assay was 0.5 ngaml. The intra-assay coef®cient of variation was 6.3% at a leptin concentration of 15.6 ngaml. The interassay coef®cients of variation were 8.8% and 5.2% at serum leptin concentrations of 2.9 and 15 ngaml, respectively.
All hormonal measurements were made in the laboratory of our Endocrinology Department.
Statistical methods
Descriptive statistical results are presented in the tables as the meansAE s.d. Since insulin and triglyceride concentrations signi®cantly deviated from a normal distribution, measurements were log-transformed for analysis. These variables were then transformed back to their natural units for presentation in tables showing adjusted means. Patients and controls were compared using Student's unpaired t-test. The proportional frequencies in patients and controls were compared using the w 2 test. The relations between variables were evaluated by Pearson's correlation coef®cient (r). Signi®cance was taken as P`0.05. All analyses were conducted by StatgraphicsaPC V 5.0 statistical software (Statistical Graphics Corporation, USA). (Table 5) . Fasting serum insulin concentrations were not signi®cantly different in patients than controls (Table 5) .
Thyroid function was normal in all patients and did not differ with respect to normal controls. Serum free thyroxine concentration (an index of ef®ciency of replacement doses of L-thyroxine) showed no signi®-cant difference between patients and controls (14.4 AE 4.3 vs 15.3 AE 2.9 pmolal, P NS).
Patients had lower IGF-1 concentrations than controls (64.8AE 81.2 vs 184.5AE 71.0 ngaml, P`0.001). GH-de®cient adults had signi®cantly higher fasting serum leptin concentrations compared with healthy controls with similar body fat mass (23.5AE 11.8 vs 11.7AE 6.9 ngaml, P 0.01, Table 5 ). This difference remained signi®cant even when expressed in relation to fat mass percentage (0.79AE 0.40 vs 0.42AE 0.17 ngaml%, P`0.05) and kg of fat mass (1.32AE 0.81 vs 0.66AE 0.30 ngaml kg, P`0.05, Table 6 ).
Higher leptin concentrations were observed in female patients compared to female controls, but differences did not reach statistical signi®cance (24.9 AE 12.3 vs 14.5AE 7.1 ngaml, P NS). Body fat percentage and fat mass (kg), lean body percentage Correlations between leptin concentrations and study parameters
Serum leptin values were positively associated with percentage body fat (r 0.81, P`0.01) and age (r 0.81, P`0.01) in the control subjects, but demonstrated no relation to WHR, free thyroxine, IGF-1, glucose, insulin, total cholesterol, triglyceride, HDL, LDL or VLDL cholesterol concentrations, lean body mass (percentage and kg), and body water mass (percentage and l) in the control group. In this group correlations between leptin and BMI (r 0.60, P 0.06), and leptin and body fat (kg) (r 0.61, P 0.06) were near to statistical signi®cance. In the patient group no signi®cant correlation was found between leptin and BMI, age, WHR, free thyroxine, IGF-1, glucose, insulin, triglyceride, HDL-, LDL-, VLDL cholesterol concentrations, lean body mass (percentage and kg), body fat mass (percentage and kg) and body water mass (percentage and l). Interestingly, a strong correlation was observed between leptin and total cholesterol concentrations (r 0.83, P 0.01). This was the sole signi®cant correlation found in the patient group.
Discussion
When given conventional replacement therapy, patients with hypopituitarism show an increased mortality from cardiovascular disease 18, 19, 29 and increased prevalence of cardiovascular risk factors. 16,25,26,30 ± 32 There is no clear explanation for this observation, although GH de®ciency has been proposed as the most possible explanation. 18, 19 Our hypopituitary patients had signi®cantly higher triglyceride, total and LDL cholesterol and signi®cantly lower HDL cholesterol concentrations. This lipid pro®le constitutes a vascular risk. Our hypopituitary women had a more atherogenic lipid pro®le than male patients. An adverse effect of hypopituitarism on lipid status in women compared to men has previously been demonstrated. 26, 31 Thus, hypopituitarism with conventional replacement therapy is associated with an unfavourable fasting lipid pro®le, particularly in women. Findings from this and previous studies might contribute to explain the increased vascular mortality and morbidity in hypopituitarism, particularly in women.
In our study signi®cant positive correlations were observed between leptin concentrations, percentage body fat and age in the control group. Correlation between leptin and BMI was near statistical signi®-cance. Strong correlation between leptin and percent body fat is well known. 5 Previous studies also showed a less strong correlation between leptin and BMI when compared with leptin and percent body fat. 7, 9, 33 The correlation between leptin and age was investigated and gave discrepant results. 9, 14, 33, 34 Positive relationships with age were also reported in normal controls 5 and in diabetics. 35 Our result is in agreement with the latter ®ndings. In our GH-de®cient patients no signi®cant correlations were observed between leptin and BMI, percentage body fat or fat mass (kg). These ®ndings suggest that in the GH-de®cient situation, serum leptin concentrations are regulated by more important factor(s) than body fat. It is interesting to ®nd a strong correlation between total cholesterol and leptin concentrations in GH-de®cient hypopituitary adults; both leptin and total cholesterol are assumed to be increased in GH de®ciency. The mechanism(s) of increased leptin concentrations and the causal relationship to increased cholesterol concentrations are open to speculation. Only one previous study showed a weak positive correlation between leptin and total cholesterol in a randomly selected population. 11 Other studies failed to show such a relationship in patients or controls. 9, 33 The relationship between GH, IGF-1 and leptin has been thoroughly investigated, but has given con¯ict-ing results 10 ± 12,14,36 ± 38 In our study, leptin concentrations were found to be signi®cantly higher in GHde®cient patients as a whole compared with healthy controls with similar fat mass. When leptin concentrations were expressed in relation to fat mass (kg) or fat percentage signi®cant increases persisted. When male and female patients and controls were analysed separately, increases of leptin concentrations in the patients did not reach statistical signi®cance, but this may be explained by the relatively small sample size of subgroups. Control subjects had leptin concentraLeptin and growth hormone de®ciency N Ozbey et al tions similar to those previously reported in healthy controls. 5, 33, 38 Our results might indicate increased production of leptin by per unit fat mass in GH de®ciency similar to the reported increase in ob messenger RNA content of adipocytes in obese humans. 5 Previous studies showed different results regarding leptin concentrations in GH de®ciency. Florkowski et al 7 showed that plasma leptin concentrations in GH de®ciency did not differ signi®cantly than those reported previously in GH-suf®cient subjects of comparable BMI. In these patients GH treatment decreased plasma leptin in accordance with decreased percentage total body fat. The authors suggested that GH has no independent effect upon leptin in GH-de®cient adults. Miyakawa et al 14 showed that serum leptin concentrations in GH de®-cient patients were not different from those in normal subjects adjusted for percentage body fat mass, but in acromegalics, serum leptin concentrations were signi®cantly lower than those in normal subjects after correcting for percentage body fat. Krzyzanowska et al 13 showed that adiposity corrected plasma leptin concentrations (leptinapercentage fat mass and leptinafat mass) in GH de®ciency did not differ from controls. These ratios were signi®cantly lower in acromegalics than those found in controls. Nystrom et al 11 found that GH-de®cient patients have higher leptin values than control subjects of similar BMI. Norrelund et al 6 showed increased leptin in GHde®cient patients, but in these studies no additional measures of adiposity other than BMI were performed. Norrelund suggested that increased leptin concentrations may re¯ect the increased total body fat of the patients compared with controls of similar BMI. Al-Shoumer et al 9 reported that leptin concentrations are raised in GH-de®cient hypopituitary adults to a greater extent than would be expected from the degree of obesity. However, in this study body composition by bioelectrical impedance analysis was not assessed for all study subjects and leptin concentrations expressed in relation to fat mass were not determined. Our results are, in part, in agreement with the three latter ®ndings, but despite having similar fat mass, our patients had signi®cantly higher leptin concentrations than controls, thereby con¯icting with Norrelund's suggestion. The nature of our data does not allow us to draw any conclusion on the mechanisms of increased leptin concentrations in GH de®ciency. Direct and indirect inhibitory effects of GH on leptin production may theoretically explain our ®ndings. Some evidence has emerged recently to support this suggestion.
Houseckneckt et al 39 studied subcutaneous adipose tissue culture collected from castrated male cattle. In this system no effect could be de®ned when adipose tissue culture was supplemented with GH, but GH prevented the stimulation of leptin expression by insulin or dexamethasone in adipose tissue culture. In vivo they showed that short-term administration of GH increased leptin mRNA expression in subcutaneous adipose tissue obtained from the hip of castrated male cattle. In addition, plasma insulin was increased two-fold with GH administration. It is not clear whether the increase in leptin concentrations may be in part caused by increased insulin secretion after administration of GH. In vitro effects of GH on adipose tissue culture might explain the increased leptin concentrations in GH-de®cient adults. It might be thought that absence of GH may increase the sensitivity of adipose tissue to stimulants of leptin synthesis such as insulin and glucocorticoids, but it is unclear at the present time whether this observation could be applicable to humans.
Gill et al 10 studied 21 elderly (61 ± 83 y) GH de®cient patients and 22 gender and BMI matched controls (61 ± 88 y). Male patients had increased fat mass but similar lean mass compared with controls. Leptin concentrations per unit fat mass were identical in male patients and controls. Female patients had lower lean mass but similar fat mass to controls and their leptin concentrations per unit fat mass were twice that of the controls. In this study leptin was determined positively by fat mass and negatively by lean mass. It is concluded that decrease in lean mass without a change in fat mass increases leptin concentrations by increasing cellular leptin production. If this is operative, then leptin concentrations may re¯ect the total body composition rather than the amount of the fat mass. Our hypopituitary patients had lower lean body mass (kg) compared with controls as a whole, but it is unlikely that elevated leptin concentrations could be attributed to decreased lean mass in our patients, because we could not ®nd any signi®cant correlation between leptin and lean body mass both in the patients and controls. The results of Gill et al obtained from elderly subjects seem not to be applicable to our study.
It is suggested that higher leptin concentrations in GH de®cient hypopituitary adults might be explained by the hypothalamic damage resulting from the pituitary tumours or from treatment with radiotherapy andaor surgery. In our study, hypopituitary women with Sheehan's syndrome in whom selective ischaemic damage to the pituitary developed 40 did not have signi®cantly different leptin concentrations compared with women in whom hypopituitarism resulted from pituitary tumour andaor surgery radiotherapy (leptin concentrations 22.4AE 18.8 vs 27.4AE 1.90 ngaml for patients with Sheehan's syndrome and pituitary tumours respectively, P NS). This suggestion does not seem to explain the increased leptin concentrations in hypopituitarism.
Another possible mechanism that can explain increased leptin in GH de®ciency is the development of an acquired resistance to leptin at the central level, like that observed in obese subjects. 5, 41 In obesity it is shown that weight loss improves the sensitivity to leptin, indicating that decreased central sensitivity to leptin in human obesity is an acquired phenomenon. 42 GH-de®cient adults are also thought to be insensitive The effects of leptin on body composition appear to be mediated by speci®c receptors in the hypothalamus, a brain region that is critical for regulation and circadian rhythm of GH secretion. 43, 44 The leptin receptor variant without transmembrane and intracellular domains might represent the binding protein for leptin in the circulation. It has been suggested that in obese subjects abnormal binding to binding proteins may result in changes of bioavailable leptin. 45 In GH de®ciency one of the possible mechanisms for the increased leptin concentrations might be the effects of GH on binding proteins or leptin clearance 46 Ð an area that has not yet been investigated.
In summary, hypopituitary patients with GH de®-ciency showed an abnormal lipid pro®le on conventional replacement therapy. The unfavourable lipid pro®le was particularly evident in women. Signi®-cantly higher leptin concentrations in patients were found in comparison with healthy controls with similar body fat, even after correcting for percentage body fat and body fat mass. This suggests a fat massindependent effect of GH on leptin. Decreased central sensitivity to leptin, increased leptin production per unit fat mass or alterations in leptin clearance might be operative.
